The viral and non-viral vector manufacturing market is projected to grow at an annualized rate of over 15%, claims Roots Analysis
The
rapidly growing pipeline of genetically modified therapies reflects the surge
in demand for high quality vectors, presenting lucrative opportunities for
companies with the capabilities to manufacture viral and non-viral gene
delivery solutions
London
Roots Analysis has announced the addition of “Viral Vectors,
Non-Viral Vectors and Gene Therapy Manufacturing Market
(4th Edition) 2021 – 2030” report to its list of offerings.
Over time, ~15 cell and gene therapies have been
approved across the world. Since transgene delivery into biological producing
cell lines, gene modified cell-based therapies and the body, is an
indispensable aspect of modern drug / therapy development efforts, high quality
vectors are required by both medical researchers, drug developers and
manufact7uring service providers, alike. In order to save time and costs, many
stakeholders in the cell and gene therapy market have opted to outsource their
vector manufacturing needs.
To order this 685+ page report, which features
170+ figures and 290+ tables, please visit https://www.rootsanalysis.com/reports/view_document/viral-vectors-non-viral-vectors-and-gene-therapy-manufacturing-market-/274.html
Key Market Insights
The market features
the presence of over 225 industry players and non-industry players
It is currently
dominated by the presence of mid-sized players (51-500 employees), which
represent more than 55% of industry stakeholders, worldwide. Of these, ~80% are
capable of synthesizing different types of viral vectors, and round 10% of
the companies mentioned in the report claim to have expertise in manufacturing
plasmid DNA.
Over the time,
several new technology platforms have been developed to deal with existing
production-related challenges
Majority (85%) of the
available technologies are currently focused on viral vectors. The technology landscape analysis featured in the report,
highlights the fact that 55% of the contemporary platforms are meant for the
development and production of gene therapies.
Close to 210
partnerships were inked in this market, over the last five years
More than 55% of
partnerships were inked post 2017, with the maximum activity being reported in
2020 (till September). Most of the deals (~27%) were manufacturing
agreements, followed by product / technology licensing (24%), product
development (17%) and R&D (9%) agreements.
Expansion activity in
this domain has grown at a CAGR of 97%, between 2015 and 2020
Most of the reported
expansions were related to the establishment of new facilities / plants (52%),
followed by facility expansions (22%), indicative of the initiatives undertaken
by service providers to cope with the rapidly increasing demand for good
quality vectors.
The installed vector manufacturing capacity is estimated to
be 63,000+ L
The majority share of
the available vector manufacturing capacity belongs to companies with both
clinical and commercial scale facilities (~70%). In fact, 65% of the estimated
global vector producing capacity belongs to the larger and more established
stakeholders in the market.
Till 2030, the annual demand for vectors is expected grow
at an annualized rate of 21%
Currently, North America and Europe contribute to more than 70% of the
demand for viral and non-viral vectors. By 2030, the demand, in terms of number
of patients in need to interventions requiring some form of vector, is
projected to be over 220,000.
The developed markets
are likely to remain the major contributors, in terms of service revenues, to
the market
The majority share of
service revenues is anticipated to come from vector manufacturing project for
oncological disorders (~55%). By 2030, the need for gene delivery solutions for
commercialized therapies, is expected to be responsible for 60% of the annual
service revenues, representing a CAGR of 39%.
To request a sample copy / brochure of
this report, please visit https://www.rootsanalysis.com/reports/274/request-sample.html
Key
Questions Answered
§
Who are the leading
players (contract service providers and in-house manufacturers) engaged in the development
of vectors and gene therapies?
§ Which
global regions are the considered as (contract) manufacturing hubs for vectors
and gene therapies?
§ What
kind of technologies are used / being developed by stakeholders engaged in this
domain?
§ What
kind of companies are likely to partner with vector manufacturing service
providers?
§ Which
types of partnership models are commonly adopted by stakeholders in this
industry?
§ What
are the different types of expansions that have been undertaken by vector
manufacturers?
§ What
are the emerging types of viral and non-viral vectors used in the manufacturing
of genetically modified therapies?
§ How
has the COVID-19 pandemic impacted the viral and non-viral vector, and gene
therapy manufacturing market?
§ What
is the current, global demand for viral and non-viral vectors, and gene therapies?
§
How is the current
and future market opportunity likely to be distributed across key market
segments?
The USD 2.5+ billion (by 2030) financial
opportunity associated with viral vector, non-viral vector and gene therapy
manufacturing market has been analyzed across the following segments:
§ Scale
of operation
§
Lab
§
Clinical
§
Commercial
§ Type
of Vector
§
AAV
§
Adenoviral
§
Lentiviral
§
Retroviral
§
Plasmid DNA
§
Others
§ Application
Area
§
Gene Therapy
§
Cell Therapy
§
Vaccine
§ Therapeutic
Area
§
Oncological Disorders
§
Inflammation & Immunological Disorders
§
Neurological Disorders
§
Ophthalmic Disorders
§
Muscle Disorders
§
Metabolic Disorders
§
Cardiovascular Disorders
§
Others
§ Geographical
Regions
§
North America
§
Europe
§
Asia-Pacific
§
MENA
§
Latin America and Rest of the World
The report also
features inputs from eminent industry stakeholders, according to whom, the
anticipated increase in demand for cell and gene therapies, is the most
prominent driver of the growth of the vector supply market. The report includes
detailed transcripts of discussions held with the following experts:
§
Menzo Havenga (Chief
Executive Officer and President, Batavia Biosciences)
§
Nicole Faust (Chief
Executive Officer & Chief Scientific Officer, CEVEC Pharmaceuticals)
§
Jeffrey Hung (Chief
Commercial Officer, Vigene Biosciences)
§
Cedric Szpirer
(Founder, Executive & Scientific Director, Delphi Genetics)
§
Olivier Boisteau,
(Co-Founder / President, Clean Cells), Laurent Ciavatti (Ex-Business
Development Manager, Clean Cells) and Xavier Leclerc (Head of Gene Therapy,
Clean Cells)
§
Alain Lamproye
(Ex-President of Biopharma Business Unit, Novasep)
§
Joost van den Berg
(Ex-Director, Amsterdam BioTherapeutics Unit)
§
Bakhos A Tannous
(Director, MGH Viral Vector Development Facility, Massachusetts General
Hospital)
§
Eduard Ayuso, DVM,
PhD (Scientific Director, Translational Vector Core, University of Nantes)
§
Colin Lee Novick
(Managing Director, CJ Partners)
§
Semyon Rubinchik
(Scientific Director, ACGT)
§
Astrid Brammer
(Senior Manager Business Development, Richter-Helm)
§
Marco Schmeer
(Project Manager, Plasmid Factory) and Tatjana Buchholz (Ex-Marketing Manager,
Plasmid Factory)
§
Brain M Dattilo
(Business Development Manager, Waisman Biomanufacturing)
§
Beatrice Araud (ATMP
Key Account Manager, EFS-West Biotherapy)
§
Nicolas Grandchamp
(R&D Leader, GEG Tech)
The research includes
profiles of key players (listed below), featuring a brief overview of
the company, its financial performance (if available), information
related to its manufacturing facilities, proprietary vector manufacturing
technology and an informed future outlook.
§
Advanced BioScience
Laboratories
§
Aldevron
§
Audentes Therapeutics
§
BioReliance
§
Brammer Bio
§
bluebird bio
§
Emergent BioSolutions
§
FUJIFILM Diosynth
Biotechnologies
§
MeiraGTx
§
MassBiologics
§
Spark Therapeutics
§
Vigene Biosciences
§
Biovian
§
Cobra Biologics
§
Centre for Process
Innovation
§
FinVector
§
Kaneka
Eurogentec
§
Lonza
§
MolMed
§
Novasep
§
Orchard
Therapeutics
§
Oxford BioMedica
§
Richter-Helm
§
Sanofi
§
uniQure
§
Vibalogics
§
VIVEbiotech
§
Cell and Gene
Therapy Catapult
§
Wuxi AppTec
For additional
details, please visit
https://www.rootsanalysis.com/reports/view_document/viral-vectors-non-viral-vectors-and-gene-therapy-manufacturing-market-/274.html or
email sales@rootsanalysis.com
You may also be
interested in the following titles:
1.
Gene Therapies Market (4th
Edition) by Therapeutic Approach (Gene Augmentation, Oncolytic Viral Therapy,
Immunotherapy and Others), Type of Gene Therapy, Type of Vectors Used,
Therapeutic Areas (Autoimmune Disorders, Cardiovascular Diseases, Genetic
Disorders, Hematological Disorders, Metabolic Disorders, Muscle-related
Diseases, Oncological Disorders, Ophthalmic Diseases and Others), Route of
Administration, and Key Geographical Regions: Industry Trends and Global
Forecasts, 2020-2030
2.
Global T-Cell (CAR-T, TCR, and
TIL) Therapies Market (5th Edition): Distribution by Type of Therapy (CAR-T, TCR
and TIL), Target Indications (Acute Lymphoblastic Leukemia, NHL, Melanoma,
Bladder Cancer, Lung Cancer, Head and Neck Cancer, Multiple Myeloma and
Others), Target Antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100 and
others), Key Players and Key Regions (North America, Europe, Asia Pacific,
Latin America, MENA, and Rest of the World): Industry Trends and Global
Forecasts, 2021-2030
3.
Biopharmaceutical
Contract Manufacturing Market (4th Edition) by Type of
Product (API, FDF), Scale of Operations (Preclinical, Clinical and Commercial),
Expression System (Mammalian, Microbial and Others), Company Size (Small,
Mid-sized, Large and Very Large), Biologics (Antibody, Vaccine, Cell Therapy
and Other Biologics) and Key Geographical Regions (North America, Europe,
Asia-Pacific, MENA and LATAM)- Industry Trends and Global Forecast to 2030
4.
Cell and Gene Therapy
CROs Market by Type of Therapy (Cell Therapy (Stem Cells, Immune Cells
and Others) and Gene Therapy), Scale of Operation (Drug Discovery, Preclinical,
Clinical and Commercialization), Preclinical Services Offered, Clinical
Services Offered, and Geography (North America, Europe, Asia-Pacific, Latin
America, MENA and Rest of the World): Industry Trends and Global Forecasts (2nd
Edition), 2021-2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots
Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
Comments
Post a Comment